Everything below concerns HPLC-UV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
== Types == Addiction is described in two broad forms: substance use disorders, which involve psychoactive drugs, and behavioral addictions, which involve activities that produce reward without a drug. Whether some patterns of eating meet the criteria for addiction remains disputed.
==== Dopamine ==== Dopamine is the principal prolactin-inhibiting factor. It acts on D2 receptors (D2R) on the lactotroph membrane. Two D2R isoforms (D2L and D2S) couple to Gi/Go proteins and produce inhibition through multiple time-dependent mechanisms:
APCs undergo a process of maturation while migrating, via chemotactic signals, to lymphoid tissues, in which they lose the phagocytic capacity and develop an increased ability to communicate with T-cells by antigen-presentation. As well as in CD8+ cytotoxic T cells, APCs need pMHC-II and additional costimulatory signals to fully activate naive T helper cells.
Sources: en.wikipedia.org
=== Critical reviews === The first episode of the series received positive reviews with Rotten Tomatoes giving it a 100% rating with 9 reviews from critics. Metacritic gave the series a 77% rating based on six reviews. Ben Travers of IndieWire wrote, "Its sense of humor may call to mind Conan O'Brien's absurdist Late Night work, and the visual style may hearken back to Johnny Carson's era, but John Mulaney isn't trying to make another late-night talk show. He's trying to make his". Alison Herman of Variety described the show as being "consistently delightful chaos" adding, "Part of what made Everybody's in LA so exciting was in how it took the cultural decline of the talk show as an opportunity. Rather than subjecting itself to the endless grind of daily headlines or relying on stars' promotional schedules to book guests, the show would embrace the niche fascination its genre was already trending toward — treating 'talk show' like an aesthetic to be tried on and toyed with, not a set of expectations to be met."
1993/1063) A43 Trunk Road (Silverstone Bypass) (Detrunking) Order 1993 (S.I. 1993/1064) North Norfolk Action (Miscellaneous Provisions) Order 1993 (S.I. 1993/1065) Gipsy Encampments (Metropolitan District of Sefton) Order 1993 (S.I. 1993/1066) Airports Slot Allocation Regulations 1993 (S.I. 1993/1067) Oldham National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1068) Cornwall and Isles of Scilly Mental Handicap National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/1069) Merchant Shipping (Vessels in Commercial Use for Sport or Pleasure) Regulations 1993 (S.I. 1993/1072) Aviation Security (Air Cargo Agents) Regulations 1993 (S.I. 1993/1073) Vocational Training (Public Financial Assistance and Disentitlement to Tax Relief) (Amendment) Regulations 1993 (S.I. 1993/1074) Plymouth Development Corporation (Planning Functions) Order 1993 (S.I. 1993/1075) Social Security (Consequential Provisions) (Northern Ireland) Act 1992 Appointed Day Order 1993 (S.I. 1993/1079) Vocational Training (Tax Relief) (Amendment) Regulations 1993 (S.I. 1993/1082) Peak Rail Light Railway Order 1993 (S.I. 1993/1083) Dacorum and St Albans Community National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1084) Rochdale Healthcare National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1085) Horizon National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/1086) Bexley and Greenwich (London Borough Boundaries) Order 1993 (S.I. 1993/1091) Insurance Companies (Cancellation No.
=== Treatment === Consumption of Amanita virosa is a medical emergency requiring hospitalization. There are four main categories of therapy for poisoning: preliminary medical care, supportive measures, specific treatments, and liver transplantation. Preliminary care consists of gastric decontamination with either activated carbon or gastric lavage. However, due to the delay between ingestion and the first symptoms of poisoning, it is commonplace for patients to arrive for treatment many hours after ingestion, potentially reducing the efficacy of these interventions. Supportive measures are directed towards treating the dehydration which results from fluid loss during the gastrointestinal phase of intoxication and correction of metabolic acidosis, hypoglycemia, electrolyte imbalances, and impaired coagulation. No definitive antidote for amatoxin poisoning is available, but some specific treatments have been shown to improve survivability. High-dose continuous intravenous penicillin G has been reported to be of benefit, though the exact mechanism is unknown, and trials with cephalosporins show promise. There is some evidence that intravenous silibinin, an extract from the blessed milk thistle (Silybum marianum), may be beneficial in reducing the effects of death cap poisoning. Silibinin prevents the uptake of amatoxins by hepatocytes, thereby protecting undamaged hepatic tissue; it also stimulates DNA-dependent RNA polymerases, leading to an increase in RNA synthesis. N-acetylcysteine has shown promise in combination with other therapies.
Sources: en.wikipedia.org
Joy Osmanski as Paula Brooks / Tigress (season 3; recurring season 1; guest season 2):A member of the ISA who hunts the world's most dangerous humans. She is a gym teacher at Blue Valley High, the wife of "Crusher" Crock, and mother of Artemis Crock. In the second season, she breaks out of prison twice. In the third and final season, she moves in next door to the Whitmore-Dugans. Joel McHale as Sylvester Pemberton / Starman and Gerard Shugel / Ultra-Humanite (season 3; guest season 1; recurring season 2):A member of the original JSA who used an anti gravity Cosmic Staff invented by scientist Ted Knight that Courtney later finds. In the present, Ultra-Humanite forms an alliance with Icicle and Dragon King before transplanting his brain into Sylvester Pemberton's body in order to manipulate Stargirl and her JSA, and Dragon King's brain into Ultra-Humanite's albino gorilla body for him to "defeat" as Starman alongside Jordan's son before intending to run for president as a mouthpiece for Icicle to spread his ideals.
United States (US) US food safety regulations have set a maximum permitted level of 20 μg/kg for aflatoxin B1, in combination with the other aflatoxins (B2, G1 and G2) in all foods, with the exception of milk which has a maximum permitted level of 0.5 μg/kg. Higher levels of 100–300 μg/kg are tolerable for some animal feeds. European Union (EU) The EU has set maximum permitted levels for aflatoxin B1 in nuts, dried fruits, cereals and spices to range from 2–12 μg/kg, while the maximum permitted level for aflatoxin B1 in infant foods is set at 0.1 μg/kg. The maximum permitted levels for aflatoxin B1 in animal feeds set by the EU range from 5–50 μg/kg and these levels are much lower than those set in the US. Joint United Nations' Food and Agriculture Organization (FAO)/World Health Organization (WHO) Expert Committee on Food Additives (JECFA) The FAO/WHO JECFA has set the maximum permitted levels of aflatoxin B1 in combination with the other aflatoxins (B2, G1 and G2) to be 15 μg/kg in raw peanuts and 10 μg/kg in processed peanuts; while the tolerance level of aflatoxin B1 alone is 5 μg/kg for dairy cattle feed.
To reduce the effects of the testosterone flare at the initiation of GnRH agonist therapy in men Androgen-dependent skin and hair conditions such as acne, seborrhea, excessive hair growth, and scalp hair loss in women as well as high testosterone levels due to polycystic ovary syndrome (PCOS) in women, at 25 to 50 mg/day generally in combination with a birth control pill Feminizing hormone therapy for transgender women usually at 50 mg/day in combination with an estrogen. Peripheral precocious puberty in boys at 12.5 to 100 mg/day in combination with an aromatase inhibitor like anastrozole, especially for familial male-limited precocious puberty (testotoxicosis) Overly long-lasting erections in men at 50 mg per week to 50 mg every other day The medication has been suggested for but has uncertain effectiveness in the following indication:
=== Targeted sanctions === In jurisdictions not subject to comprehensive sanctions, only transactions related to specific parties are prohibited. Jurisdictions that face targeted sanctions may continue to do business with the United States, with restrictions only placed on specific categories of individuals or entities, and anyone worldwide who materially supports or provides financial, logistical, or technological support for them. According to OFAC, there are approximately 12,000 names on the Specially Designated Nationals and Blocked Persons List (SDN list), which is the most restrictive category of targeted U.S. sanctions, targeting U.S.-designated terrorists, officials and beneficiaries of certain authoritarian regimes, and international criminals such as drug traffickers by blocking their U.S. assets and restricting U.S. persons from engaging in any transactions with them. The following jurisdictions have a specific OFAC sanctions program for SDN designations targeting individuals or entities engaging in sanctionable activities:
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.